A Tale Of Two DMD Drugs: Theme And Variation In Controversial US FDA Reviews

 
• By Michael McCaughan

Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.

stack of different kind porous chocolate pieces on a dark background.
Sponsors should focused on how the differences stacked up between two controversial reviews at the US FDA.

More from Rare Diseases

More from Pink Sheet